MicroRNAs (miRNAs) are a class of small non-coding singlestranded RNAs of B22 nucleotides in length that regulate protein levels by binding to either partially or complete complementary sites in messenger RNAs (mRNAs), leading to translational repression or transcript degradation, respectively. MiRNAs have a role in critical biological processes including cellular growth and differentiation. Recent studies showed that miRNAs have an important role in the pathogenesis of multiple myeloma (MM) and that miRNA signatures are associated with different cytogenetic subtypes. Unsupervised analyses of miRNA expression in MM identified unique clusters, which were not associated with chromosomal abnormalities, while supervised analysis showed a specific miRNA expression pattern for MM subgroups. [1] [2] [3] We have investigated the expression level of 365 miRNAs in sorted bone marrow (BM) plasma cells of 45 newly diagnosed MM patients enrolled in the HOVON-65/GMMG-HD4 trial (Supplementary Table S1 ) and 4 healthy individuals (Gene Expression Omnibus, http://www.ncbi.nlm.nih.gov/geo/, accession number GSE16558). 1 We addressed the question whether MM patients could be classified based on miRNA expression patterns. MiRNA expression data were linked to gene expression data to gain more insight into candidate miRNA target genes.
Finally, a possible association of miRNA expression with response to therapy, that is, complete response (CR), nearly CR (nCR), progression-free survival (PFS) and overall survival (OS), was evaluated.
Unsupervised hierarchical cluster analysis based on miRNA expression showed that normal BM samples clustered distinctly from MM samples ( Figure 1 ). A total of 44 MM samples were grouped in four distinct clusters and one MM sample was not included in any MM cluster. The robustness indices per cluster are shown in Supplementary Table S2 . To determine the miRNA expression signatures of the four MM and one normal BM cluster, each cluster was compared with the remaining clusters using the Mann-Whitney U-test with a false discovery rate (FDR)o0.05 (Partek Genomics Suite 6.4 software). The top 10 significant distinctive miRNAs for the four MM clusters and normal BM cluster are shown in Tables 1 and 2 , respectively. The complete list of differentially expressed miRNAs (FDRo0.05) characterizing the four MM clusters and normal BM cluster is shown in Supplementary Tables S3 and S4 , respectively. MM cluster 1 (n ¼ 8) was characterized by upregulation of 17 miRNAs, including miRNA-130a, -424 and -622; MM cluster 2 (n ¼ 9) by upregulation of miRNA-576 and -106b; MM cluster 3 (n ¼ 4) by upregulation of 23 miRNAs, including miRNA-372 and -200a, and downregulation of miRNA-146b; and MM cluster 4 (n ¼ 23) was characterized by downregulation of 60 miRNAs. An interesting observation is the identification of a miRNA signature of MM cluster 4 comprised of upregulated miRNAs including miRNA-21, -19a and -19b, which have all been shown to be involved in the signal transducer and activator of transcription 3 (STAT3) and interleukin-6 (IL-6) anti-apoptotic pathway, representing a putative mechanism for the malignant growth of myeloma plasma cells. 3 In addition, members of miRNA clusters miRNA-17B92 (miRNA-19a, -19b and -92) and miRNA-106B25 (miRNA-106b, -93 and -25) were highly represented in the miRNA signature of MM cluster 4. Pichiorri et al. 3 recently described a miRNA signature in MM, which is characterized by upregulation of miRNA-17B92 and miRNA-106B25 clusters. The miRNA-17B92 cluster has an oncogenic role by regulating expression of its pro-apoptotic targets, such as phosphatase and tensin homolog (PTEN), E2F transcription factor 1 (E2F1) and BCL2-like 11 (BCL2L11). 4 Furthermore, this cluster was shown to have an essential role in B-cell development. The miRNA-106B25 cluster may have a similar function because E2F1 and BCL2L11 have also been described as targets of this miRNA cluster.
The normal BM cluster showed 40 upregulated miRNAs and 1 downregulated miRNA (FDRo0.05) compared with MM patient samples ( Table 2 and Supplementary Table S4 ). We confirmed upregulation of six miRNAs (miRNA-214, -135b, -196a, -155, -203 and -486) in normal BM samples, which have been described by Gutiérrez et al. Figure 1 Unsupervised analysis of miRNA expression. The relative quantification method, 2 ÀDCt , was used to calculate the expression. A log2 transformation was performed to obtain a normal linear distribution. Hierarchical clustering of average linkage with the centered correlation metric was performed for unsupervised analysis using BRB Array tools version 3.8.0. Samples are depicted in columns, miRNAs in rows. The color scale bar represents the relative miRNA expression normalized using the relative quantification method, 2
ÀDCt , with red representing positive expression (upregulation) and blue representing negative expression (downregulation) of a miRNA. Four MM clusters and one normal bone marrow (nBM) cluster with distinctive miRNA expression profiles were identified. An additional cluster of one sample was not defined (MM-1). Translocation and clinical data are shown under the dendogram and heatmap. Green indicates no chromosomal abnormality present; red, chromosomal abnormality; and gray, not determined. Concerning response, green indicates nCR/CR, red, pVGPR and gray, not determined.
A supervised analysis using the Mann-Whitney U-test with a FDRo0.05 for each cytogenetic subgroup (deletion 13q14, t(4;14), t(11;14), t(14;16) was performed to investigate the expression patterns of miRNAs among cytogenetic subgroups of MM. Despite the small size of the group, we identified five miRNAs that were differentially expressed in MM patients with a t(11;14) and one miRNA in t(14;16). The five miRNAs were deregulated in two MM patients with t(11;14) (miRNA-122a, -33, -489, -519e, -555), whereas these were upregulated compared with the remaining MM patients. These miRNAs were located on different chromosomes, which did not include chromosome 11 or 14. MiRNA-600, located at chromosome 9, was upregulated in the MM patient harboring a t(14;16) compared with the remaining MM patients. The miRNA expression patterns were not associated with 13q14 deletion or t(4;14).
We could not identify a specific miRNA expression-based predictor for good responders (nCR/CR), PFS or OS. Association studies of individual miRNAs with clinical response log-rank tests showed three upregulated miRNAs that were associated with a better OS at borderline significance level after correction for multiple testing using a step-up approach, 5 that is, let-7f (FDR ¼ 0.06), miRNA-194 (FDR ¼ 0.06) and miRNA-296 (FDR ¼ 0.06) (Figure 2) . One of these miRNAs, miRNA-296, has a significant adverse impact on survival in esophageal squamous cell carcinoma. Interestingly, a higher expression of miRNA-296 predicted a better survival in our study. MiRNA-296 is involved in drug resistance through regulation of apoptosis and adenosine triphosphate-binding cassette (ABC) transporter ABCB1 (MDR1). MiRNA let-7f also promotes angiogenesis by targeting antiangiogenic genes. In lung cancers, it has been shown that low levels of let-7 correlated with shorter survival after resection, which correspond with our finding that a low level of let-7f is associated with shorter OS. In addition, we found that upregulation of miRNA-194 is associated with a better OS in MM. Interestingly, Pichiorri et al. 6 showed that miRNA-194 inhibits cell growth and enhances apoptosis in MM cell lines in a p53-dependent manner. Furthermore, they showed that miRNA-194 targets murine double minute 2 (MDM2) and suggested that a combination of this miRNA with miRNA-192, -215 and a p53 activator could be a successful therapy for MM.
Finally, we investigated the effect of DICER1, DROSHA and AGO1, three genes required for miRNA biogenesis, on survival in MM patients. MM patients were divided into high-and lowexpression groups for all three genes and log-rank tests were performed. A FDR was calculated using a step-up approach 5 to compensate for multiple testing errors. Interestingly, a better PFS was identified at borderline significance level (FDR ¼ 0.07) in patients having a low DICER1 expression level ( Figure 3 ).
MiRNAs function primarily as translational repressors by binding to mRNA, which results in mRNA degradation and protein translation inhibition. Combinatory analysis of mRNA and miRNA levels is used for detection of miRNA targets. We determined the mRNA expression profile of 39/45 MM patients for whom sufficient RNA was available using the Human Genome U133 Plus 2.0 Array. Our approach assumes an To determine the miRNA expression signature of clusters, a Mann-Whitney U-test was applied for each cluster using the Partek Genomics Suite 6.4 software. A FDR was calculated using a step-up approach with a 0.05 significance value to compensate for multiple testing errors. For each cluster the top 10 (or less) up-and/or downregulated miRNAs in comparison with the remaining clusters are shown.
inverse correlation if a functional interaction between miRNA and mRNA is present. Spearman's rank correlation test identified 130 inverse correlations with Po0.001. Prediction scores were calculated using four of the currently available target prediction programs, including TargetScan 5.1, PicTar, miRDB and miRBase, and only those miRNA-mRNA pairs that were identified by at least three prediction programs were selected (Table 3 ). This analysis identified 18 miRNA-mRNA inverse correlations, including 11 miRNAs and 15 genes. Three of these miRNA-mRNA interactions have been experimentally validated previously; miRNA-21 has been shown to target programmed cell death 4 (PDCD4), 7 as well as reversion-inducing-cysteinerich protein with kazal motifs (RECK). The miRNA-mRNA interactions concerning miRNA-21 have been validated by quantitative reverse transcription-PCR. MiRNA-21 is upregulated in a wide variety of cancers and has been described as an oncogenic miRNA exhibiting an anti-apoptotic role. In myeloma cells, miRNA-21 has been shown to be upregulated as well. 3, 8 The tumor suppressor gene PDCD4 is downregulated or lost in several tumor types. Therefore, PDCD4 has been opted as a molecular target in cancer treatment. In addition, downregulation of PDCD4 is essential for maximal induction of activating protein 1 upon RAS oncogenes. RECK has been shown to be involved in angiogenesis, through inhibition of matrix metalloproteinase2 (MMP2) and MMP9. 9 Furthermore, miRNA-21 has been identified as a STAT3 target gene. STAT3 is an important mediator of IL-6 signaling, which is essential for Figure 2 Overall survival of MM patients according to miRNA expression. Log-rank tests for univariate association with OS were performed for each of the 365 miRNAs. MiRNA expression was divided into four quartiles. Log-rank tests were performed for quartile 1 (Q1) vs Q2-Q4, and Q4 vs Q1-Q3 to identify up-and downregulated miRNAs, respectively. A FDR was calculated for each log-rank P-value using a step-up approach, Another interesting inverse correlation that we found is between CDC34 and let-7, which has also been shown recently in primary fibroblasts. In this study let-7 expression led to downregulation of CDC34 and G 2 /M cell cycle arrest through the cyclin-dependent kinase CDC2 and Wee 1. However, the function of these genes in MM remains to be elucidated.
In conclusion, the study presented here demonstrates that miRNA expression in MM is deregulated compared with normal plasma cells. Unsupervised analysis showed that MM patients can be classified according to their miRNA expression pattern. An important question that remains is what drives this miRNA clustering in MM patients. Functional studies on the miRNAs that define the clusters may reveal the answer to this question in the future.
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2 Leukemic stem cells (LSCs) may also benefit from the microenvironment, to favor their proliferation and resistance towards treatment, as demonstrated within the endosteal region. Given the structuring capacities of MSCs, they may represent a crucial target for LSCs to create their own microenvironment and prosper. Thus, major publications confirm that targeting the stromal support can help to eradicate LSCs in vivo.
3
Others and we have shown that b-catenin, the terminal effector of canonical Wnt signaling, was overactivated in acute myeloid leukemia (AML) and correlated with a greater risk of relapses. 4 Importantly, no mutations of b-catenin have been described in AML, suggesting that signaling defects are not only intrinsic to LSCs, but also result from abnormal niche behavior and activity. Interestingly, we have disclosed a new AML subtype where leukemic progenitors overexpress the focal adhesion kinase (FAK) protein, a key-signaling partner of integrins that is not expressed by immature normal progenitors. 5 FAK was overexpressed in half of AML cases and correlated with poor prognosis. The overexpression of FAK conferred increased drug resistance to AML cells and its regulation was independent from adhesion, as described in other cancers. Furthermore, FAK and b-catenin activities were correlated in leukemic cells 6 (Despeaux et al., in preparation). As our previous data had shown that FAK-expressing AML (FAK þ AML) and FAK À AML were two distinct entities that behaved oppositely in terms of Wnt signaling, we aimed to determine whether BM MSCs isolated from those AML patients exhibited specific structural or functional abnormalities relative to oxidative inflammatory and Wnt signaling.
Study was performed on FAK þ and FAK À AML patients whose clinico-biological characteristics are shown in Table 1 , and comparison was made with age-matched healthy-donors. Obtention, isolation and culture of primary cells were performed as previously described. 5, 7 After 21 days of culture, isolated BM MSCs displayed an enriched CD45 (Figure 1a) . FAK þ AML-derived BM MSCs showed decreased clonogenic potential, increased senescence and no apoptosis (not shown), compared with healthy donor BM MSCs (Figure 1a) . Oppositely, apart from increased proliferation, FAK À AML-derived BM MSCs behaved normally.
We (Figure 1b) . Furthermore, data obtained under contactless conditions, or after a pretreatment of leukemic cells with paraformaldehyde or FAK inhibitor PF-573228, suggested that physical contact and FAK activity must be present to affect BM MSCs (Figure 1c) .
As LSCs are thought to pattern their microenvironment to support their maintenance and resistance we checked whether the CD45 À CD34 hi CD38 À/lo CD123 þ LSC-enriched population could alone alter the phenotype of healthy donor-derived BM 
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MSCs. FAK þ LSCs were able to recapitulate senescence, even if seeded at a lower density than bulk cells (3.7 Â 10 3 cells/cm 2 versus 2.5 Â 10 5 cells/cm 2 ), without affecting clonogenic capacities (Figure 1d) . Interestingly, compared with the influence of normal CD34 þ cells, we measured an enrichment in the CAR phenotype within the BM MSCs population when cocultured with FAK þ LSCs or blasts (Figures 1b-d) for which physical interactions and FAK activity were both mandatory. þ AML cells were respectively checked as described in Figure 1 . (Figure 2b) . Moreover, if IL-6, IL-8 and angiopoietin-1 expression depended only on FAK activity, stroma-derived factor-1 upregulation necessitated also adhesion in accordance with the mandatory role of adhesion for CAR phenotype induction (Figure 2c ). Sorted FAK þ LSCs triggered an inflammatory, senescent and CAR phenotype in BM MSCs as well (Figure 2d) .
Another key regulator of normal and AML immature cells is Wnt signaling. We have focused our analysis on Wnt-5a, dickkopf-1 (Dkk-1) and secreted frizzled-related protein-1 (sFRP-1), which are key Wnt regulators of the hematopoietic niche, assessing mRNA levels of the Wnt ligands by semiquantitative reverse-transcription PCR. Compared with their normal counterpart, FAK þ and FAK À AML-derived BM MSCs were respectively characterized by high levels of Wnt-5a and sFRP-1 mRNA (Figure 3a) . These alterations were recapitulated upon coculture conditions, as FAK þ AML cells induced an increase of Wnt-5a mRNA in BM MSCs, together with a decrease of Dkk-1 mRNA, without affecting sFRP-1 expression compared with the influence of their normal counterpart ( Figure 3b) 

